Susumu Aikou et al demonstrated that serum TFF-3 could be an effective marker of GC with sensitivity of 80.9% and specificity of 81.0%, while the combination of serum TFF-3 and SPG statistical significantly improved tumor detection as compared to TFF3 or SPG alone[57]. The gene discussed is TFF3; the disease is neoplasm.